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Abstract:   In 1984 an epizootic of eastern equine encephalitis (EEE) virus killed 7 of 39 (18%) whooping cranes in captivity at 
the Patuxent Wildlife Research Center in Laurel, Maryland, USA.  Since that time whooping cranes have been vaccinated with a 
human EEE vaccine.  This vaccine was unavailable for several years, necessitating use of an equine vaccine in the cranes.  This 
study compared the antibody titers measured for three years using the human vaccine with those measured for two years using the 
equine form.  Whooping cranes developed similarly elevated titers in one year using the human vaccine and both years using the 
equine vaccine.  However, in two years where the human vaccine was used, the whooping cranes developed significantly lower 
titers compared to other years.
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 Eastern Equine Encephalitis (EEE) is a clinically important 
disease of horses, people, and some birds including whooping 
cranes (Grus americana). EEE is classified as a zoonotic vector-
borne alpha virus. The virus is found in eastern North America 
and is maintained and amplified by a mosquito-wild bird cycle. 
Native wild passerines carry the virus and initiate the cycle, 
with viremic birds being found 37-51 days before virus is first 
detected in mosquitoes beginning in July or August and lasting 
through October (Crans et al. 1994). The virus is then spread 
by the mosquitoes and amplified in the hatch-year passerines. 
EEE does not typically produce morbidity or mortality in native 
passerines, but has been known to cause mortality in non-native 
birds (pheasants, emus; Tengelsen 2001), horses, bats (Main 
1979), and humans.
 Vaccination as a tool to control arbovirus infections in 
horses is a widespread practice that provides effective protec-
tion (American Association of Equine Practitioners, 1995; Ten-
glesen et al. 2001). Commercially available equine vaccines 
for EEE are used to protect emus from the disease (Tengelson 
et al. 2001). Between September 17 and December 5, 1984 an 
epizootic of EEE killed 7 of 39 captive whooping cranes at 
the Patuxent Wildlife Research Center, Laurel, Maryland USA 
(Dein et al. 1986, Carpenter et al. 1989). Following the 1984 
EEE epizootic at Patuxent, all whooping cranes began receiv-
ing annual injections of EEE vaccine (Clark et al. 1987; Ol-
sen et al. 1997). There were no challenge studies done with the 
endangered whooping cranes.  Naturally occurring epizootics 
were documented in sentinel birds and in mosquitoes, with no 
morbidity or mortality in captive whooping cranes.  This led 
to the conclusion that the vaccination program was efficacious 
(Olsen et al. 1997). In 2000 and 2001, the human EEE vaccine 
previously used was not available for the whooping cranes at 
Patuxent.  As an alternative; the birds were vaccinated with a 
commercially available equine vaccine. 
 The objective of this study was to compare antibody titer 
levels observed in years when the human vaccine was used with 
the 2 years when the equine vaccine was used.  When an equine 
vaccine was first tested in the 1980’s, the titer levels were lower 
than those seen with the human vaccine (Clark et al. 1987), and 
we wanted to discover if this was still true with the currently 
available equine vaccine.
METHODS
 All adult whooping cranes housed at Patuxent were kept 
in 15 x 20 m outdoor pens. Very young whooping crane chicks 
being costume-reared for release programs spent the first 7-10 
days confined indoors in 3 x 3 m pens, but afterwards were in 
indoor/outdoor pens until 40-50 days of age, after which time 
they were housed totally outside.
 All whooping crane chicks received their first injection of 
EEE vaccine in July. For 1989-1999 this was 0.5 ml intramus-
cular injection of the PE 6 WRAIR strain human EEE vaccine 
(The Salk Institute, Government Service Division, Swiftwater, 
Pennsylvania, USA).  This was followed 1 month later by an in-
tramuscular injection of 1.0 ml. Yearly revaccination using the 
same 1.0 ml dose of the PE 6 WRAIR EEE vaccine occurred 
in late August or early September, to coincide with the seasonal 
peak of activity (August-October) for the EEE carrying mos-
quito (Culiseta melanura) at Patuxent (Pagac et al, 1992). 
 In 2000 and 2001, all adult whooping cranes received a 
1.0 ml intramuscular dose of Encephaloid M (EEE and west-
ern equine encephalitis vaccine, Fort Dodge Laboratories, Fort 
Dodge, Iowa USA) in August of each year. All whooping crane 
chicks received the same Encephaloid M as 0.5 ml intramuscu-
larly in July and 1.0 ml intramuscularly in August of their hatch 
year.
 Blood samples to obtain serum for titers were collected 
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in late October or early November of each year during rou-
tine health examinations of the whooping cranes. Serum was 
shipped frozen to the USGS National Wildlife Health Center, 
Madison, Wisconsin, USA for analysis by hemaglutination-
inhibition testing (HI, 1994-1997) or by serum neutralization 
testing (SN, 2000-2001) at the National Veterinary Services 
Laboratory, Ames, Iowa, USA.  We analyzed the EEE titers for 
1994, 1996 and 1997, years in which the human vaccine was 
used, and the most recent years (2000, 2001) when the equine 
vaccine was used.  Due to budget constraints, no titers had been 
tested in 1995, 1998 or 1999.
 Data were analyzed with a repeated measure analysis of 
variance (ANOVA) using a compound symmetry model in the 
mixed-models procedure of SAS (Statistical Analysis System, 
Version 6.12; 1997). The subject factor was crane identification 
number nested with gender. Prior to analysis, titers were trans-
formed with a log 10 transformation to help achieve normality 
and homoscedasticity of residuals. Pairwise comparisons were 
performed on the least square means using a Tukey multiple 
comparison procedure (P < 0.05).
RESULTS AND DISCUSSION
 Antibody titers were available from a total of 52 whooping 
cranes for the years 1994-1997 (human vaccine) and 2000-2001 
(equine vaccine).  For the 3 years when the human vaccine was 
used, the titers were highly variable (Table 1). The titers for 
1994 were very low, while the 1996 titers were high, equiva-
lent to those found with the equine vaccine. The 1997 titers 
were higher than 1994 but lower than 1996. Table 1 shows the 
untransformed means, sample sizes, and standard deviations, 
as well as pairwise comparison results of the log-transformed 
least square means. The mean titers for 1996, 2000, and 2001 
were not significantly different (P > 0.05) from each other. The 
titer means for 1994 and 1997 were significantly different from 
each other and were different from 1996, 2000, 2001 EEE mean 
titers (P < 0.05).  We used two different tests to determine the 
titers (HI and SN) but saw no differences in titer levels in 1996 
(HI), 2000 or 2001 (SN).  Titers seen with the human vaccine 
were considered protective due to the absence of morbidity or 
mortality seen in whooping cranes in years since 1984 when 
EEE was detected in mosquitoes and sentinel birds (Olsen et 
al. 1997).  The equine vaccine tested produced titers equal to or 
higher than those produced by the human vaccine, which would 
suggest adequate protection.
 Initial testing of a commercially available equine EEE vac-
cine and the Salk human EEE vaccine in the 1980’s had shown 
superior titer levels when using the human vaccine (Clark et. 
al, 1987). Therefore, the decision was made to vaccinate the 
captive whooping cranes with the human vaccine. Unavailabil-
ity of this vaccine starting in 2000  prompted the switch to an 
equine form of EEE vaccine. These results show that the titers 
obtained from this new equine EEE vaccine equal or exceed the 
titers seen with the human EEE vaccine used in the past.  The 
human vaccine continues to be unavailable today, and, given 
current world events, it is unlikely to be released by the military 
any time soon.  Therefore, continued use of an equine EEE vac-
cine appears to be an appropriate management tool to prevent 
this disease in captive whooping cranes.    
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Table 1.  Geometric mean, sample size, standard error, and Tukey’s multiple comparison 
test of eastern equine encephalitis virus antibody titers measured in whooping cranes 
(Grus americana) at Patuxent Wildlife Research Center, Laurel, Maryland USA, 1994-
2001.
a  Means with the same letter are not significantly different (P > 0.05), based on 
Tukey’s multiple comparison procedure of the least square means generated from 
the log-transformed titer levels in the repeated measures ANOVA.
Year       Sample Size (n)   Geometric Mean        Standard Error        Tukey’s testa
1994               33                         6.08                         1.22                          A 
1996               39                       88.13                         1.21                          B 
1997               37                       15.07                         1.21                          C 
2000               52                       81.23                         1.19                          B 
2001               51                       82.64                         1.19                          B 
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